We are live on
!
Find out more
Antipodes Partners Portfolio holdings
AUM
$5.46B
Turnover
36.94%
1-Year Est. Return
26.64%
This Fund
S&P 500
This Quarter
Est. Return
+9.77%
1 Year Est. Return
+26.64%
3 Year Est. Return
+96.4%
5 Year Est. Return
+160.76%
10 Year Est. Return
–
AUM
$4.46B
AUM Growth
+$1.23B
(+38%)
Cap. Flow
+$903M
Cap. Flow
% of AUM
20.27%
Top 10 Holdings %
Top 10 Hldgs %
37.6%
Holding
139
New
33
Increased
39
Reduced
42
Closed
23
Avg Time Held Equity + Options
1
year
Top 10 Avg Time Held Equity + Options
1.5
years
Top 20 Avg Time Held Equity + Options
1.5
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
1.5
years
Top 20 Avg Time Held Equity only
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ferrovial N.V. Ordinary Shares
FER
|
+$167M |
| 2 |
Exelon
EXC
|
+$156M |
| 3 |
Ameren
AEE
|
+$137M |
| 4 |
Sempra
SRE
|
+$136M |
| 5 |
Crown Castle
CCI
|
+$128M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$108M |
| 2 |
Microsoft
MSFT
|
+$91.6M |
| 3 |
Barrick Mining
B
|
+$63.5M |
| 4 |
Johnson Controls International
JCI
|
+$58.9M |
| 5 |
Capital One
COF
|
+$53.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Utilities | 29.08% |
| 2 | Healthcare | 12.43% |
| 3 | Technology | 11.96% |
| 4 | Financials | 8.08% |
| 5 | Materials | 7.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Bruker
BRKR
$8.61B
| $265K | 0.01% |
8,168
+1,380
| +20% | +$49.2K |
2025 Q1
2 quarters
|
|
77
monday.com
MNDY
$3.99B
| $252K | 0.01% |
+1,303
| New | +$300K |
2025 Q3
0 quarters
|
|
78
argenx
ARGX
$53.2B
| $212K | ﹤0.01% |
287
-45
| -14% | -$29.7K |
2022 Q4
11 quarters
|
|
79
Tidewater
TDW
$3.94B
| $179K | ﹤0.01% |
+3,362
| New | +$184K |
2025 Q3
0 quarters
|
|
80
PubMatic
PUBM
$812M
| $158K | ﹤0.01% |
+19,065
| New | +$194K |
2025 Q3
0 quarters
|
|
81
Certara
CERT
$1.47B
| $150K | ﹤0.01% |
12,285
+5,620
| +84% | +$61.5K |
2024 Q3
4 quarters
|
|
82
Immunome
IMNM
$2.05B
| $128K | ﹤0.01% |
10,892
+631
| +6% | +$6.28K |
2025 Q1
2 quarters
|
|
83
Structure Therapeutics
GPCR
$1.58B
| $114K | ﹤0.01% |
4,078
+1,146
| +39% | +$22.8K |
2024 Q2
5 quarters
|
|
84
Abbott
ABT
$181B
| $111K | ﹤0.01% |
828
+87
| +12% | +$11.4K |
2025 Q1
2 quarters
|
|
85
Chime Financial
CHYM
$11.3B
| $109K | ﹤0.01% |
5,402
+402
| +8% | +$11.4K |
2025 Q2
1 quarter
|
|
86
DexCom
DXCM
$33.1B
| $109K | ﹤0.01% |
1,617
+773
| +92% | +$61.2K |
2025 Q1
2 quarters
|
|
87
Schrodinger
SDGR
$1.91B
| $98.5K | ﹤0.01% |
4,912
+3,660
| +292% | +$73.5K |
2025 Q1
2 quarters
|
|
88
Steris
STE
$21.9B
| $87.1K | ﹤0.01% |
352
+92
| +35% | +$22K |
2025 Q1
2 quarters
|
|
89
Cencora
COR
$65.2B
| $83.1K | ﹤0.01% |
266
+62
| +30% | +$18.2K |
2025 Q2
1 quarter
|
|
90
Transocean
RIG
$6.15B
| $77.5K | ﹤0.01% |
+24,838
| New | +$74.9K |
2025 Q3
0 quarters
|
|
91
Qiagen
QGEN
$9.53B
| $68.2K | ﹤0.01% |
1,526
-1,040
| -41% | -$49.8K |
2025 Q1
2 quarters
|
|
92
MYR Group
MYRG
$4.45B
| $62.6K | ﹤0.01% |
301
-403
| -57% | -$75.2K |
2024 Q2
5 quarters
|
|
93
Establishment Labs
ESTA
$1.83B
| $53.6K | ﹤0.01% |
1,307
-741
| -36% | -$30.3K |
2025 Q1
2 quarters
|
|
94
Natera
NTRA
$58.3B
| $53.1K | ﹤0.01% |
330
+17
| +5% | +$2.69K |
2025 Q1
2 quarters
|
|
95
Thermo Fisher Scientific
TMO
$258B
| $47.5K | ﹤0.01% |
+98
| New | +$45.6K |
2025 Q3
0 quarters
|
|
96
908 Devices
MASS
$491M
| $45.8K | ﹤0.01% |
5,227
-1,331
| -20% | -$8.84K |
2025 Q1
2 quarters
|
|
97
Henry Schein
HSIC
$9.69B
| $41.9K | ﹤0.01% |
632
+46
| +8% | +$3.18K |
2025 Q2
1 quarter
|
|
98
GE Aerospace
GE
$324B
| $41.2K | ﹤0.01% |
137
-94
| -41% | -$25.7K |
2023 Q4
7 quarters
|
|
99
Ingersoll Rand
IR
$30.2B
| $40.2K | ﹤0.01% |
486
+173
| +55% | +$14.2K |
2023 Q4
7 quarters
|
|
100
iRhythm Holdings
IRTC
$3.6B
| $37.8K | ﹤0.01% |
220
-35
| -14% | -$5.56K |
2025 Q2
1 quarter
|
|
Similar funds
SCM
Antipodes Partners's Q3 2025 Portfolio in Review
As of Q3 2025, Antipodes Partners held 139 positions worth $4.46B, up 38% from $3.22B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Antipodes Partners deployed $903M of net new capital in Q3 2025, opening 33 new positions and adding to 39 existing holdings. Its largest new stake was Ferrovial N.V. Ordinary Shares: 3,097,701 shares worth $176M.
By sector, the portfolio is most concentrated in Utilities at 29% of assets, up from 3.7% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $108M trimmed.
- Antipodes Partners's largest Q3 2025 buy was Ferrovial N.V. Ordinary Shares: 3,097,701 shares worth $176M.
- Antipodes Partners added most to Exelon in Q3 2025, an estimated $156M increase.
- Antipodes Partners's biggest Q3 2025 reduction was Alphabet (Google) Class A, cutting an estimated $108M.
- Antipodes Partners fully exited Micron Technology in Q3 2025, selling an estimated $49.7M.
- Antipodes Partners's ten largest holdings make up 38% of its $4.46B portfolio in Q3 2025.
- Antipodes Partners opened 33 new positions and closed 23 in Q3 2025.
- Antipodes Partners's portfolio value rose 38% quarter-over-quarter to $4.46B.
Based on Antipodes Partners's 13F filing for Q3 2025, filed 10 Nov 2025.